⚠ RecallRadar📷 ScanGuidesOfficial U.S. recall notices, restated plainly

Imprimis NJOF, LLC: Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West

DrugsSource: FDA (drug) · Date: 2026-01-14

Read the official notice at FDA (drug) →

Share on XFacebookRedditEmail

Get alerts for Imprimis NJOF

Guides: Which agency handles which recall (FDA vs USDA vs CPSC vs NHTSA)

The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.

Company / brand
Imprimis NJOF, LLC
Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Reason / hazard
Presence of particulate matter - Glass like particles.
Classification
Class II
Status
Ongoing
Distribution / sold at
U.S Nationwide
Recall initiated
2025-12-18
Code info
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Product quantity
314 boxes of 6,280 pre-filled syringes
Voluntary mandated
Voluntary: Firm initiated
City
Ledgewood
State
NJ
Country
United States
Event id
98181
Free daily digest + "My products" watchlist

Get the daily digest, and tell us what to watch. Everything is optional except your email.

Free allergen alerts:

Categories:

Privacy: we store only what you enter here, use it only to send recall alerts you asked for, never sell or share it, and you can unsubscribe anytime. Double opt-in: we will email you a confirmation link before sending anything; alerts start only after you confirm. Every email has unsubscribe and manage-watchlist links.